Atomo Diagnostics Ltd. (AU:AT1) has released an update.
Atomo Diagnostics Ltd.’s Q3 FY24 report shows a significant rise in sales orders, exceeding 520k units for their HIV Self-Test, marking increased global demand and expansion into new markets like Colombia. The company is also advancing in rapid test development with a $3m consortium grant to create a Group Strep B test, contributing to a 25% year-to-date revenue increase. Atomo ends the quarter debt-free, with a strong cash position of $5.2m.
For further insights into AU:AT1 stock, check out TipRanks’ Stock Analysis page.